Evidence map›Paper›PMID 40585173›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Early Genetic Evolution of Driver Mutations in Uveal Melanoma.

James J Dollar, Christina L Decatur, Ezekiel Weis, Amy C Schefler, Miguel A Materin, Timothy S Fuller, Alison H Skalet, David A Reichstein, Ivana Kim, Kisha D Piggott and 22 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors.

James J DollarDepartment of Ophthalmology and Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0003-2416-4272
Christina L DecaturDepartment of Ophthalmology and Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0001-9125-1718
Ezekiel WeisDepartment of Ophthalmology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.ORCID 0000-0002-6862-0850
Amy C ScheflerRetina Consultants of Texas, Houston, TX.ORCID 0000-0001-9829-8164
Miguel A MaterinDepartment of Ophthalmology, Duke University, Durham, NC.ORCID 0000-0001-9097-9512
Timothy S FullerTexas Retina Associates, Dallas, TX.
Alison H SkaletDepartment of Ophthalmology and Casey Eye Institute, Oregon Health and Science University, Portland, OR.
David A ReichsteinTennessee Retina, Nashville, TN.
Ivana KimDepartment of Ophthalmology and Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA.
Kisha D PiggottDepartment of Ophthalmology and Visual Sciences, Washington University, St. Louis, MO.
Hakan DemirciDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI.
Thomas A AabergRetina Specialists of Michigan, Foundation for Vision Research, and Michigan State University College of Human Medicine, Grand Rapids, MI.ORCID 0000-0003-4160-2844
Prithvi MruthyunjayaDepartment of Ophthalmology and Byers Eye Institute, Stanford University, Stanford, CA.ORCID 0000-0003-1087-9736
Basil K WilliamsDepartment of Ophthalmology, University of Cincinnati, Cincinnati, OH.
Eugene ShildkrotDepartment of Ophthalmology, University of Virginia, Charlottesville, VA.
Scott C N OliverDepartment of Ophthalmology and Sue Anschutz-Rodgers Eye Center, University of Colorado, Aurora, CO.ORCID 0000-0002-3654-6502
Devron H CharTumori Foundation, San Francisco, CA.
Antonio CaponeAssociated Retina Consultants, Royal Oak, MI.
John MasonDepartment of Ophthalmology, University of Alabama, Birmingham, AL.
Scott D WalterRetina Consultants, Hartford, CT.
Michael AltaweelDepartment of Ophthalmology, University of Wisconsin, Madison, WI.
Jill WellsDepartment of Ophthalmology, Emory University, Atlanta, GA.
Dan S GombosSection of Ophthalmology, Department of Head and Neck Surgery, The University of Texas, MD Anderson Cancer Center, Houston TX.
Jay DukerDepartment of Ophthalmology and New England Eye Center, Tufts University, Boston, MA.
Peter HovlandColorado Retina Associates, Denver, CO.
Tony TsaiRetinal Consultants Medical Group, Sacramento, CA.
Cameron JavidRetina Associates, Tucson, AZ.
Michael A DuranteDepartment of Ophthalmology and Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0003-3137-6847
Kyle R CovingtonCastle Biosciences, Friendswood, Texas.
Song ZhangO'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX.
Zelia M CorreaDepartment of Ophthalmology and Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0003-2946-3757
J William HarbourSimmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-1104-9809

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
Proteomics CoreP30EY010572 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI John Peter Campbell · 1995 to 2026
$19.4M
Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Victor L Perez · 2004 to 2026
$12.2M
Stem Cell, Organoid and Cell Phenotyping ModuleP30EY030413 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI W MATTHEW PETROLL · 2019 to 2026
$5.9M
MOLECULAR PREDICTIVE TESTING IN OCULAR MELANOMAR01CA125970 · NCI · WASHINGTON UNIVERSITY · PI CORREA, ZELIA MARIA, HARBOUR, JAMES WILLIAM · 2006 to 2021
$4.9M
NCI NIH HHS P30 CA142543NCI NIH HHS P30 CA240139NCI NIH HHS R01 CA125970NEI NIH HHS P30 EY010572NEI NIH HHS P30 EY014801NEI NIH HHS P30 EY030413
6 · The paper itself

Abstract

Uveal melanoma (UM) is an aggressive cancer of the eye that frequently results in metastatic death. UMs are most likely to metastasize when they are small, at a time when they are difficult to distinguish from benign nevi and often observed without treatment. Unfortunately, little is known about the early genetic evolution of UM or potential biomarkers to indicate small tumors undergoing malignant transformation. Here, we performed targeted next generation sequencing for the 7 canonical UM driver mutations in 1140 primary UMs, including 131 small early-stage tumors. We found that the evolutionary burst of genetic aberrations that determines the archetypal UM subtypes and metastatic propensity has already occurred by the time most small tumors are biopsied, although a significantly larger proportion of small tumors are still evolving compared to larger tumors. We found that the 15-gene expression profile (15-GEP) support vector machine discriminant score was the best indicator of tumors in transition from low-risk Class 1 to high-risk Class 2 signature. While

Indexed as

Cancer mutationsCancer prognosisChoroidal melanomaMolecular PrognosticationPrognostic biomarkersProspective studiesSurvival analysisUveal melanoma

Identifiers

PMID40585173
PMCPMC12204427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.